Monopar Therapeutics Inc.
MNPRHealthcareNASDAQBiotechnology · Last scanned Jun 1, 2026
Scan Results
Daily timeframeMonopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. With a market capitalization of $435.7M, it sits in small-cap territory. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89.
Market Cap
$435.7M
Beta
1.50
P/E (TTM)
—
P/E (Fwd)
-20.21
EPS (TTM)
$-1.93
EPS (Fwd)
$-3.22
ROE
-15.9%
ROA
-12.1%
Cash
$137.5M
Total Debt
$230,425
Free CF
-$5.4M
52W Change
116.7%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $137.5M in cash comfortably exceeding the $230K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$5.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -15.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
A beta of 1.50 means MNPR is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing MNPR's risk profile alongside its fundamentals and technical indicators provides a more complete picture.